0
0
Vaccine makers Biontech and Pfizer plan to seek approval to administer a third dose of their Covid 19 vaccine. They said yesterday they plan to submit relevant data to the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other regulatory agencies “in the coming weeks.”
“Although protection against severe disease remains high for six months, a decline in efficacy against symptomatic cases over time and the emergence of variants can be expected,” the two companies said. Therefore, a third dose may be needed six to 12 months after the first vaccination.
Working on serum against delta variant
Initial data from a study showed that a third vaccination with the Biontech vaccine increased the amount of antibodies five- to 10-fold. The companies also reportedly expect a third dose to be reliably effective against the highly contagious delta variant of the coronavirus.
German company Biontech is also currently working on a vaccine specifically designed to protect against the delta variant. The first samples are in production at a plant in Mainz, Germany. Clinical trials could begin in August, according to Biontech and its U.S. partner Pfizer.
- source:ORF.at/agencies/picture: pixabay.com
This post has already been read 771 times!
